CTOs on the Move

Swift Biosciences

www.swiftbiosci.com

 
Swift Biosciences is a biotechnology company that is developing novel molecular biology technologies to better characterize and understand the genome. We are an energetic, highly innovative company focused on creating tools to advance the DNA sequencing sciences. Our products are designed to help customers analyze challenging samples that are often associated with translational work, including circulating, cell-free DNA and formalin-fixed, paraffin-embedded samples.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Swift Biosciences raised $12.2M on 06/30/2017

Similar Companies

BioCurex

BioCurex is a Rancho Santa Margarita, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

kinetix pharm

kinetix pharm is a Medford, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthTell

HealthTell is committed to empowering the next generation of diagnostics and therapeutics for complex immune-mediated diseases such as cancer, autoimmune disorders, and infectious diseases. Based on robust proprietary technology, HealthTell is developing the first and only diagnostic platform capable of assessing an individual`s immune system response to specific diseases. Applicable to a broad range of therapeutic areas, HealthTell is empowering physicians and patients to proactively manage health and make more informed decisions.

4C Medical Technologies

4C Medical Technologies, Inc. is a medical device company developing a novel minimally invasive solution for the treatment of mitral regurgitation (MR).

Carisma Therapeutics

Carisma Therapeutics Inc. is a clinical stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. The first applications of the platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric antigen receptor (CAR)-macrophages for the treatment of solid tumors. Carisma Therapeutics is headquartered in Philadelphia, PA.